<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(1)</volume><submitter>Enomoto Y</submitter><pubmed_abstract>&lt;h4>Objectives&lt;/h4>This study aimed to extract endoscopic findings for diagnosing colorectal neoplasia associated with sessile serrated lesions (SSLs), which are of significant interest.&lt;h4>Methods&lt;/h4>To compare the magnifying narrow-band imaging (NBI) findings with microscopic morphology, we classified SSLs into two groups: Group A SSLs included the majority of uniform SSLs and any dysplasia other than that classified as group B SSLs. Group B SSLs included SSLs with intramucosal and invasive carcinoma. We also quantitatively assessed visible vessels using ImageJ software.&lt;h4>Results&lt;/h4>This study included 47 patients with 50 group B SSLs who underwent endoscopic resection between 2012 and 2020. The results were retrospectively compared with those of 237 patients with 311 group A SSLs that underwent endoscopic resection. Using conventional white-light endoscopy, significantly more group B SSLs had uneven shapes and some reddening compared to group A SSLs. The diagnostic odds ratios for group B SSLs were as follows: lesions with a diameter ≥10 mm, 9.76; uneven shape, 3.79; reddening, 15.46; and visible vessels with NBI, 11.32. Regarding visible vessels with NBI, the specificity and diagnostic accuracy for group B SSLs were 94.9% and 93.1%, respectively. The percentage of the vascular tonal area of NBI images was significantly larger for group B SSLs than for group A SSLs (3.97% vs. 0.29%; &lt;i>p&lt;/i> &lt; 0.01).&lt;h4>Conclusions&lt;/h4>SSLs with reddening and/or a diameter ≥10 mm are suspected to contain cancerous components. Moreover, visible vessels observed using magnifying NBI can serve as objective indicators for diagnosing SSLs with cancerous components with a high degree of accuracy.</pubmed_abstract><journal>DEN open</journal><pagination>e315</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10690695</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Advantage of magnifying narrow-band imaging for the diagnosis of colorectal neoplasia associated with sessile serrated lesions.</pubmed_title><pmcid>PMC10690695</pmcid><pubmed_authors>Saito S</pubmed_authors><pubmed_authors>Chino A</pubmed_authors><pubmed_authors>Igarashi M</pubmed_authors><pubmed_authors>Shimizu R</pubmed_authors><pubmed_authors>Matsuda T</pubmed_authors><pubmed_authors>Enomoto Y</pubmed_authors><pubmed_authors>Yasue C</pubmed_authors><pubmed_authors>Igarashi Y</pubmed_authors><pubmed_authors>Fujisaki J</pubmed_authors><pubmed_authors>Ishioka M</pubmed_authors><pubmed_authors>Kobayashi H</pubmed_authors><pubmed_authors>Ide D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Advantage of magnifying narrow-band imaging for the diagnosis of colorectal neoplasia associated with sessile serrated lesions.</name><description>&lt;h4>Objectives&lt;/h4>This study aimed to extract endoscopic findings for diagnosing colorectal neoplasia associated with sessile serrated lesions (SSLs), which are of significant interest.&lt;h4>Methods&lt;/h4>To compare the magnifying narrow-band imaging (NBI) findings with microscopic morphology, we classified SSLs into two groups: Group A SSLs included the majority of uniform SSLs and any dysplasia other than that classified as group B SSLs. Group B SSLs included SSLs with intramucosal and invasive carcinoma. We also quantitatively assessed visible vessels using ImageJ software.&lt;h4>Results&lt;/h4>This study included 47 patients with 50 group B SSLs who underwent endoscopic resection between 2012 and 2020. The results were retrospectively compared with those of 237 patients with 311 group A SSLs that underwent endoscopic resection. Using conventional white-light endoscopy, significantly more group B SSLs had uneven shapes and some reddening compared to group A SSLs. The diagnostic odds ratios for group B SSLs were as follows: lesions with a diameter ≥10 mm, 9.76; uneven shape, 3.79; reddening, 15.46; and visible vessels with NBI, 11.32. Regarding visible vessels with NBI, the specificity and diagnostic accuracy for group B SSLs were 94.9% and 93.1%, respectively. The percentage of the vascular tonal area of NBI images was significantly larger for group B SSLs than for group A SSLs (3.97% vs. 0.29%; &lt;i>p&lt;/i> &lt; 0.01).&lt;h4>Conclusions&lt;/h4>SSLs with reddening and/or a diameter ≥10 mm are suspected to contain cancerous components. Moreover, visible vessels observed using magnifying NBI can serve as objective indicators for diagnosing SSLs with cancerous components with a high degree of accuracy.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2025-04-05T11:46:04.396Z</modification><creation>2025-04-05T11:46:04.396Z</creation></dates><accession>S-EPMC10690695</accession><cross_references><pubmed>38046435</pubmed><doi>10.1002/deo2.315</doi></cross_references></HashMap>